Navigation Links
CBLB502 in Medical News

New Drug Protects Against Radiation Damage

...ancy, and so can grow indefinitely, Gudkov said. "So, we decided to imitate pharmacologically what tumors do genetically," he said. Like flagellin, cblb502 does not act directly on apoptosis, he said. Instead, it stimulates cells in the body to make substances that give protection. A first request for ...
CBLB502 in Medical Technology

Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival Benefits as Mitigator Against Radiation-Induced Damage in Study

Chief Scientist to Present Results at 2007 American Association for Cancer Research Annual Meeting CLEVELAND, April 09, 2007 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. , announced today the results of its study of Protectan CBLB502's efficacy as a mitigator of both gastrointestinal (GI) and...

IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation

...ect of their steroid to be most predictive of survival in treated animals. Studies carried out by Cleveland BioLabs have revealed the ability of their cblb502 radioprotectant to protect non-human primates from the hematopoietic (as well as gastrointestinal) damage of gamma radiation. Also, their CBLB612 comp...
CBLB502 in other areas

Cleveland BioLabs to Present Protectan CBLB502 at 2008 BARDA Day ...

Cleveland BioLabs to Present Protectan CBLB502 at 2008 BARDA Day. - BUFFALO, NY--(MARKET WIRE)--Sep 23, 2008 -- Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) ...

Cleveland BioLabs Doses First Healthy Volunteer in Initial Safety Study ...

Cleveland BioLabs Doses First Healthy Volunteer in Initial Safety Study for Protectan CBLB502. - BUFFALO, NY--(MARKET WIRE)--Oct 15, 2008 -- Cleveland BioLabs, ...

Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival ...

Cleveland BioLabs, Inc. (Nasdaq: CBLI; BSE: CFB), announced today the results of its study of Protectan CBLB502's efficacy as a mitigator of both gastrointestinal ...

Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Mitigation Of ...

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced that recent primate studies have demonstrated the efficacy of Cleveland BioLabs's Protectan CBLB502 as a mitigator ...

2007 Annual Report

Thus, Protectan CBLB502 reduces injury from acute stresses by mobilizing ... Potential applications for Protectan CBLB502 include reduction of radiation therapy ...

News: Cleveland BioLabs Receives First U.S. Patent Allowance for Its ...

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that it has received a Notice of Allowance from the U.S. Patent ... Evidence of CBLB502's mechanism of ...
Other Tags
(Date:7/27/2014)... 2014 The constant expansion of companies ... demand for enterprise video. Additional factors that have increased ... areas such as corporate communication, learning and development, security ... all these factors the enterprise video market value has ... reach $35.57 billion in 2018 with a compound annual ...
(Date:7/27/2014)... 27, 2014 The North American security ... at $1570 million in 2014, and it is expected ... of 4.64%. The report incorporates the factors that influence ... of growth rates and projected total expenditure. The report ... global markets. Apart from the general overview of the ...
(Date:7/27/2014)... York City (Sunday July 27 11:45 am ... operationsinfection at the surgical sitehas been reduced by ... participation in the American College of Surgeons National ... a new case study presented at the 2014 ... Vancouver, British Columbia, reportedly reduced its rate of ...
(Date:7/27/2014)... The report provides market analysis ... Market Analysis (Commercial Aviation And Defense Aviation Landing ... - Forecasts 2014 - 2019." The report covers ... shape the market during the study period. It ... that are currently prevailing in the global market. ...
(Date:7/27/2014)... 2014 As Tylenol lawsuits ... move forward in federal court, Bernstein Liebhard LLP ... of the benefits purportedly associated with acetaminophen, the ... which appears in the The Lancet, looked at ... whom were given either acetaminophen or a placebo ...
Breaking Medicine News(10 mins):Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:Surgical safety program greatly reduces surgical site infections for heart operations 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 3Health News:Surgical safety program greatly reduces surgical site infections for heart operations 4Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 2Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 3Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 4
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
Other Contents